title: Evaluation of the Swedish adjustable gastric band VC (SAGB-VC) in an Australian population: early results.
abstract: BACKGROUND
  The Swedish adjustable gastric band VC (SAGB-VC) has been in use in Australia since 2007. We evaluated its efficacy and safety.
  
  
  METHODS
  We retrospectively analyzed the prospective clinical data of patients who received the implant between November 2007 and June 2009 at 3 Australian bariatric centres.
  
  
  RESULTS
  In all, 1176 patients (mean age 45.9 [standard deviation (SD) 12.3] yr, mean body mass index 43.4 [SD 7.6]) received the SAGB-VC. At a mean follow-up of 11 (SD 3) months, weight reduced by a mean of 18.4 (SD 11.1) kg with an excess weight loss of 37.8% (SD 19.9%). Body mass index decreased (from mean 43.4 [SD 7.7] to mean 36.7 [SD 6.5], p < 0.001). Type 2 diabetes (T2DM) was reported in 167 patients and hypertension in 373. Improvement occurred in 73.5% of patients with T2DM and 31% with hypertension, with patient-reported reduction or cessation of medication. Metabolic syndrome indices improved during follow-up: high-density lipoprotein cholesterol (mean 1.3 [SD 0.3] v. mean 1.4 [SD 0.3] mmol/L, p < 0.001), triglycerides (mean 1.6 [SD 0.8] v. mean 1.3 [SD 0.7] mmol/L, p < 0.001), waist circumference (men 141 [SD 103] to 121 [SD 15] cm, women 117 [SD 14] to 105 [SD 14] cm, both p < 0.001), C-reactive protein (90.5 [SD 75.2] v. 53.3 [SD 61.9] nmol/L, p < 0.001). The complication rate was 4.2%.
  
  
  CONCLUSIONS
  The SAGB-VC is safe and effective for treating obesity and its comorbidities. The results are reproducible in separate Australian centres and consistent with published literature.
authors.affiliation: The Australian Institute of Weight Control, Adelaide, Australia. jennifer.keogh@unisa.edu.au
authors.forename: Jennifer B
authors.initials: JB
authors.lastname: Keogh
authors.forename: Anthony
authors.initials: A
authors.lastname: Brancatisano
authors.forename: Sue F
authors.initials: SF
authors.lastname: Taylor
authors.forename: Fiona
authors.initials: F
authors.lastname: McDonald
authors.forename: Roy
authors.initials: R
authors.lastname: Brancatisano
authors.forename: Jeffrey M
authors.initials: JM
authors.lastname: Hamdorf
authors.forename: Jacob
authors.initials: J
authors.lastname: Chisholm
authors.forename: Lillian
authors.initials: L
authors.lastname: Kow
authors.forename: Sara
authors.initials: S
authors.lastname: Wahlroos
authors.forename: Brendan
authors.initials: B
authors.lastname: Ryan
authors.forename: Jim
authors.initials: J
authors.lastname: Toouli
mesh_terms: D000328:Adult; D001315:Australia; D015415:Biomarkers / Q000097:blood; D001786:Blood Glucose / Q000378:metabolism; D015992:Body Mass Index; D002097:C-Reactive Protein / Q000378:metabolism; D008076:Cholesterol, HDL / Q000097:blood; D015897:Comorbidity; D003924:Diabetes Mellitus, Type 2 / Q000097:blood; D005260:Female; D005500:Follow-Up Studies; D015391:Gastroplasty / Q000009:adverse effects / Q000295:instrumentation / Q000379:methods; D006801:Humans; D006973:Hypertension / Q000150:complications / Q000188:drug therapy; D007328:Insulin / Q000097:blood; D033183:Interdisciplinary Communication; D008297:Male; D024821:Metabolic Syndrome / Q000097:blood; D008875:Middle Aged; D009767:Obesity, Morbid / Q000150:complications / Q000601:surgery*; D011446:Prospective Studies; D015203:Reproducibility of Results; D012189:Retrospective Studies; D013548:Sweden; D016896:Treatment Outcome; D014280:Triglycerides / Q000097:blood; D055105:Waist Circumference; D015431:Weight Loss
chemical_list: D015415:Biomarkers; D001786:Blood Glucose; D008076:Cholesterol, HDL; D007328:Insulin; D014280:Triglycerides; D002097:C-Reactive Protein